MSB 3.76% $1.03 mesoblast limited

Ann: FDA Accepts BLA for RYONCIL and Agrees to Priority Review, page-132

  1. 3,997 Posts.
    lightbulb Created with Sketch. 314
    The FDA would love nothing more than to stick to its normal processes. They then retain credibility. As expert doctors, such credibility is part of who they are. The alternative would be unbearable for these people. Any trump demands would drive them to self combust in anger!

    The sponsor will also not have a tarnished product.

    Thus, I trust they will be working on the priority review and approve prior to any ARDS approval.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.03
Change
-0.040(3.76%)
Mkt cap ! $1.170B
Open High Low Value Volume
$1.08 $1.09 $1.03 $7.869M 7.571M

Buyers (Bids)

No. Vol. Price($)
1 16411 $1.03
 

Sellers (Offers)

Price($) Vol. No.
$1.03 3952 2
View Market Depth
Last trade - 16.10pm 06/06/2024 (20 minute delay) ?
Last
$1.03
  Change
-0.040 ( 3.65 %)
Open High Low Volume
$1.07 $1.08 $1.03 1907057
Last updated 15.59pm 06/06/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.